Trial Profile
A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon Beta-1a) Administered Intramuscularly to Patients With Relapsing/Remitting Multiple Sclerosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2015
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Sponsors Biogen Idec
- 17 Jun 2009 New trial record